Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)

Diabetes Care

Volumn 36, Issue 9, 2013, Pages 2543-2550

  Ahrén, Bo ^a   Dimas, Aniceto Leguizamo ^b   Miossec, Patrick ^c   Saubadu, Stéphane ^c   Aronson, Ronnie ^d  

^a LUND UNIVERSITY   (Sweden)

^b Centro de Investigacion Clinica Del Pacifico   (Mexico)

^c SANOFI   (France)

^d LMC DIABETES AND ENDOCRINOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIXISENATIDE; METFORMIN; PLACEBO;

ADD ON THERAPY; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES CONTROL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INJECTION SITE REACTION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES;

EID: 84878358313     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2006     Document Type: Article

References (28)

1. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011;27: 528-542
2. Campbell RK. Clarifying the role of incretin- based therapies in the treatment of type 2 diabetes mellitus. Clin Ther 2011; 33: 511-527
3. Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10: 124-132
4. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)d preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23: 463-477
5. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ. An overview of once-weekly glucagon-like peptide-1 receptor agonistsdavailable efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011;13: 394-407
6. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35: 1225-1231
7. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dosedependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27: 1024-1032
8. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164: 58-64
9. Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011;20: 549-557
10. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformintreated patients with type 2 diabetes. Diabetes Care 2005;28: 1092-1100
11. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32: 84-90
12. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26- week, randomised, parallel-group, openlabel trial. Lancet 2010;375: 1447-1456
13. Bolli G, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide oncedaily versus placebo in patients with T2DM insufficiently controlled on metformin (GetGoal-F1) (Abstract). Diabetologia 2011;54(Suppl. 1):A784
14. Rosenstock J, Raccah D, Koranyi L, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in patients with T2DMinsufficiently controlled on metformin (GetGoal-X) (Abstract). Diabetologia 2011;54(Suppl. 1):A786
15. Ratner R, Hanefeld M, Shamanna P, et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea 6 metformin (GetGoal-S) (Abstract). Diabetologia 2011;54(Suppl. 1):A785
16. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal- L-Asia). Diabetes Obes Metab 2012;14: 910-917
17. Kapitza C, Forst T, Coester HC, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with T2DM inadequately controlled with metformin. Diabetes Obes Metab. 25 February 2013 [Epub ahead of print]
18. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid 2011;6: 67-79
19. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetesda comprehensive review. Diabetes Technol Ther 2010;12: 11-24
20. Perfetti R. Combining basal insulin analogs with glucagon-like peptide-1 mimetics. Diabetes Technol Ther 2011;13: 873-881
21. Rosenstock J, Fonseca V. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Diabetes Care 2007;30: 2972-2973
22. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-E852
23. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008;151: 123-129
24. Cersosimo E, Gastaldelli A, Cervera A, et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab 2011;96: 1763-1770
25. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagonlike peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011;60: 1561-1565
26. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
27. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6). Lancet 2009;374: 39-47
28. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25: 737-741